

CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001.

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

www.thechemopharmalaboratoriesltd.com

EMAIL: contact@thechemopharmalaboratoriesltd.com / chemopharma2011@gmail.com

STANDLONE FINANCIAL RESULTS FOR THE QUARTER ENDED ON 31ST MARCH, 2012

(Rs. in '000)

Sr. No.	Particulars	Year Ended 31st March, 2011	Year Ended 31st March, 2012
		Audited	Audited
1	Income from Operations		
	(a) Net Sales/ Income from Operations (Net of excise duty)	-	-
	(b) Other Operating Income	363	10,669
	Total Income from operations (net)	363	10,669
2	Expenses		
	(a) Cost of materials consumed	-	-
	(b) Purchases of Stock-in-trade	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	-	-
	(d) Employee benefits expenses	4	196
	(e) Depreciation and amortisation expense	113	84
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown seperately)	211	811
	i) Professional Charges	-	137
	ii) Share Registry Expenses	-	115
	Total Expenses	328	1,343
3	Profit / Loss from Operation before other Income, Finance cost and exceptional items (1-2)	35	9,326
4	Other Income	-	-
5	Profit / Loss from ordinary activities before Finance cost and exceptional items (3+4)	35	9,326
6	Finance Costs	-	-
7	Profit / Loss from ordinary activities after Finance cost but before exceptional items (5+6)	35	9,326
8	Exceptional Items	-	-
9	Net Profit/(Loss) from ordinary activities before tax (7+8)	35	9,326
10	Tax expenses	-	846
11	Net Profit/(Loss) from ordinary activities after tax (9+10)	35	8,480
12	Extra ordinary items (net of tax expenses ! ..)	-	-
13	Net Profit/ (Loss) for the period (11+12)	35	8,480
14	Share of Profit/ (Loss) of associate*	-	-
15	Minority interest *	-	-
16	Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	35	8,480
17	Paid-up equity share Capital (face value of Rs. 10/- each)	15,000	15,000
18	Reserves excluding revaluation reserve as per balance sheet of previous accounting year	51,415	51,415
19	i) Earning per share (before extraordinary items) of Rs. 10/- each) (not annualised) :		
	(a) Basic	0.02	6.22
	(b) Diluted		
19	ii) Earning per share (after extraordinary items) of Rs. 10/- each) (not annualised) :		
	(a) Basic	0.02	5.65
	(b) Diluted		



CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001.

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

www.thechemopharmalaboratoriesltd.com

EMAIL: contact@thechemopharmalaboratoriesltd.com / chemopharma2011@gmail.com

A PARTICULARS OF SHAREHOLDING			
1	Public Shareholding		
	- Number of shares	1,028,858	1,028,858
	- Percentage of shareholding	68.59	68.59
19	Promoters and Promoter Group shareholding**		
	a) Pledged/Encumbered		
	- Number of shares	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL
	- Percentage of shares (as a % of the total share capital of company)	NIL	NIL
	b) Non-Encumbered		
	- Number of shares	471,142	471,142
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100
	- Percentage of shares (as a % of the total share capital of company)	31.41	31.41

Particulars		Quarter ended 31.03.2012
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	NIL
	Received during the quarter	NIL
	Disposed of during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL

Note :

1. The above audited financial results have been taken on record by Audit Committee in their meeting on 29.06.2012 and also approved by the Board in their meeting held on 29.06.2012
2. Separate segment reporting is not applicable to the company.



Place : Mumbai
Date : 29th June 2012

By Order of the Board
For Chemo - Pharma Laboratories Limited


Director

CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001.

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

www.thechemopharmalaboratoriesltd.com

EMAIL: contact@thechemopharmalaboratoriesltd.com / chemopharma2011@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS PER CLAUSE 41 OF THE LISTING AGREEMENT

(Rs. In '000)

Sr. No.	Particulars	As at Year ended 31.03.2012	As at year ended 31.03.2011
A	<u>EQUITY AND LIABILITIES</u>		
1	Shareholders' Funds		
	(a) Share Capital	15,000	15,000
	(b) Reserves and Surplus	29,661	21,180
	Sub-total - Shareholders' Fund	44,661	36,180
2	Non-current Liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	1,197	1,197
	(d) Long-term provisions	-	-
	Sub-total - Non-Current Liabilities	1,197	1,197
3	Current Liabilities		
	(a) Short-term borrowings	-	4,290
	(b) Other current liabilities	1,395	1,683
	(c) Short-term provisions	845	-
	Sub-total - Current Liabilities	2,240	5,973
	TOTAL - EQUITY AND LIABILITIES	48,098	43,350
B	<u>ASSETS</u>		
1	Non-current Assets		
	(a) Fixed Assets	239	324
	(b) Non-current investments	16,844	28,311
	(c) Long-term Loans & Advances	15,734	14,639
	Sub-total - Non-Current Assets	32,817	43,274
2	Current Assets		
	(a) Current investments	-	-
	(b) Cash and cash equivalents	3,726	76
	(e) Short-term loans and advances	11,555	-
	(f) Other current assets	-	-
	Sub-total - Current Assets	15,281	76
	TOTAL - ASSETS	48,098	43,350

Consequent to the notification of Revised Schedule VI under the Companies Act, 1956, the Assets and Liabilities Statements for the year ended 31.03.2012 are prepared as per revised Schedule VI. Accordingly, the previous year figures have also been re-classified to conform to this year's classification.

By Order of the Board
For Chemo - Pharma Laboratories Limited

Place : Mumbai
Date : 29th June 2012



M. S. Vyas
Director